O-linked-N-acetylglucosaminylation (O-GlcNAcylation), one of the protein post-translational modifications, is the process of adding O-linked-β-D-N-acetylglucosaminylation (O-GlcNAc) to serine and threonine residues of proteins. O-GlcNAcylation regulates various fundamental cell biological processes, including gene transcription, signal transduction, and cellular metabolism. The role of dysregulated O-GlcNAcylation in tumorigenesis has been recognized, but its role in cancer therapy tolerance has not been elucidated. Therefore, this paper provides the latest evidence on the role of O-GlcNAcylation in cancer therapy responsiveness to understand the impact of O-GlcNAcylation on cancer therapy outcomes, as well as analyzing several possible mechanisms by which O-GlcNAcylation dysregulation affects cancer therapy efficacy, and discusses the possibility of O-GlcNAcylation as a cancer therapy sensitizer.
VasanNBaselgaJHymanDM.A view on drug resistance in cancer. Nature2019; 575: 299-309.
2.
SalgiaRKulkarniP.The genetic/non-genetic duality of drug 'resistance' in cancer. Trends Cancer2018; 4: 110-118.
3.
SharmaSVLeeDYLiB, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell2010; 141: 69-80.
4.
TorresCRHartGW.Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem1984; 259: 3308-3317.
5.
HartGWHousleyMPSlawsonC.Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature2007; 446: 1017-1022.
6.
BondMRHanoverJA.A little sugar goes a long way: the cell biology of O-GlcNAc. J Cell Biol2015; 208: 869-880.
7.
MaJHouCWuC.Demystifying the O-GlcNAc code: A systems view. Chem Rev2022; 122: 15822-15864.
8.
BanerjeePSHartGWChoJW.Chemical approaches to study O-GlcNAcylation. Chem Soc Rev2013; 42: 4345-4357.
9.
ChathamJCZhangJWendeAR.Role of O-linked N-acetylglucosamine protein modification in cellular (patho)physiology. Physiol Rev2021; 101: 427-493.
10.
MarshallSBacoteVTraxingerRR.Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem1991; 266: 4706-4712.
11.
FülöpNMarchaseRBChathamJC.Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc Res2007; 73: 288-297.
12.
LeeBESuhPGKimJI.O-GlcNAcylation in health and neurodegenerative diseases. Exp Mol Med2021; 53: 1674-1682.
13.
HartGWSlawsonCRamirez-CorreaG, et al. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem2011; 80: 825-858.
14.
LoPWShieJJChenCH, et al. O-GlcNAcylation regulates the stability and enzymatic activity of the histone methyltransferase EZH2. Proc Natl Acad Sci U S A2018; 115: 7302-7307.
15.
MaZChalkleyRJVossellerK.Hyper-O-GlcNAcylation activates nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling through interplay with phosphorylation and acetylation. J Biol Chem2017; 292: 9150-9163.
16.
RuanHBNieYYangX.Regulation of protein degradation by O-GlcNAcylation: crosstalk with ubiquitination. Mol Cell Proteomics2013; 12: 3489-3497.
17.
CaldwellSAJacksonSRShahriariKS, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene2010; 29: 2831-2842.
18.
GuYMiWGeY, et al. GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res2010; 70: 6344-6351.
19.
TiainenSOikariSTammiM, et al. High extent of O-GlcNAcylation in breast cancer cells correlates with the levels of HAS enzymes, accumulation of hyaluronan, and poor outcome. Breast Cancer Res Treat2016; 160: 237-247.
20.
MachacekMSaundersHZhangZ, et al. Elevated O-GlcNAcylation enhances pro-inflammatory Th17 function by altering the intracellular lipid microenvironment. J Biol Chem2019; 294: 8973-8990.
21.
SwamyMPathakSGrzesKM, et al. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat Immunol2016; 17: 712-720.
22.
LiuYWangXZhuT, et al. Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation. J Cell Physiol2019; 234: 17527-17537.
23.
LuanpitpongSChanthraNJananM, et al. Inhibition of O-GlcNAcase sensitizes apoptosis and reverses bortezomib resistance in mantle cell lymphoma through modification of truncated bid. Mol Cancer Ther2018; 17: 484-496.
24.
LeeSJLeeDEChoiSY, et al. OSMI-1 enhances TRAIL-induced apoptosis through ER stress and NF-κB signaling in colon cancer cells. Int J Mol Sci2021; 22(20): 11073.
25.
LeeHOhYJeonYJ, et al. DR4-Ser424 O-GlcNAcylation promotes sensitization of TRAIL-tolerant persisters and TRAIL-resistant cancer cells to death. Cancer Res2019; 79: 2839-2852.
26.
de QueirozRMMadanRChienJ, et al. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) homeostasis activate the p53 pathway in ovarian cancer cells. J Biol Chem2016; 291: 18897-18914.
27.
QianLYangXLiS, et al. Reduced O-GlcNAcylation of SNAP-23 promotes cisplatin resistance by inducing exosome secretion in ovarian cancer. Cell Death Discov2021; 7: 112.
28.
GriloALMantalarisA.Apoptosis: A mammalian cell bioprocessing perspective. Biotechnol Adv2019; 37: 459-475.
29.
Mohamma dRMMuqbilILoweL, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol2015; 35: S78-s103.
30.
ShiY.Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell2002; 9: 459-470.
31.
ChuhKNBattARZaroBW, et al. The new chemical reporter 6-Alkynyl-6-deoxy-GlcNAc reveals O-GlcNAc modification of the apoptotic caspases that can block the cleavage/activation of caspase-8. J Am Chem Soc2017; 139: 7872-7885.
32.
LuanpitpongSAngsutararuxPSamartP, et al. Hyper-O-GlcNAcylation induces cisplatin resistance via regulation of p53 and c-Myc in human lung carcinoma. Sci Rep2017; 7: 10607.
33.
HolochPAGriffithTS.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anticancer therapies. Eur J Pharmacol2009; 625: 63-72.
34.
YangSZXuFYuanK, et al. Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation. Lab Invest2020; 100: 777-785.
35.
KarinM.Nuclear factor-kappaB in cancer development and progression. Nature2006; 441: 431-436.
36.
YangWHParkSYNamHW, et al. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci U S A2008; 105: 17345-17350.
37.
AllisonDFWamsleyJJKumarM, et al. Modification of RelA by O-linked N-acetylglucosamine links glucose metabolism to NF-κB acetylation and transcription. Proc Natl Acad Sci U S A2012; 109: 16888-16893.
38.
YangWHKimJENamHW, et al. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol2006; 8: 1074-1083.
MizushimaNKomatsuM.Autophagy: renovation of cells and tissues. Cell2011; 147: 728-741.
41.
LiXHeSMaB.Autophagy and autophagy-related proteins in cancer. Mol Cancer2020; 19: 12.
42.
GuoBLiangQLiL, et al. O-GlcNAc-modification of SNAP-29 regulates autophagosome maturation. Nat Cell Biol2014; 16: 1215-1226.
43.
ZhangXWangLLakB, et al. GRASP55 senses glucose deprivation through O-GlcNAcylation to promote autophagosome-lysosome fusion. Dev Cell2018; 45: 245-261.e6.
44.
KimJKunduMViolletB, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol2011; 13: 132-141.
45.
PyoKEKimCRLeeM, et al. ULK1 O-GlcNAcylation is crucial for activating VPS34 via ATG14L during autophagy initiation. Cell Rep2018; 25: 2878-2890.e4.
46.
InokiKKimJGuanKL.AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol2012; 52: 381-400.
47.
XuCPanXWangD, et al. O-GlcNAcylation of Raptor transduces glucose signals to mTORC1. Mol Cell2023; 83: 3027-3040.e11.
48.
LiXYueXSepulvedaH, et al. OGT controls mammalian cell viability by regulating the proteasome/mTOR/ mitochondrial axis. Proc Natl Acad Sci U S A2023; 120: e2218332120.
49.
JinLYuanFDaiG, et al. Blockage of O-linked GlcNAcylation induces AMPK-dependent autophagy in bladder cancer cells. Cell Mol Biol Lett2020; 25: 17.
50.
BullenJWBalsbaughJLChandaD, et al. Cross-talk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK). J Biol Chem2014; 289: 10592-10606.
51.
WangLChenSZhangZ, et al. Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer. BMC Cancer2018; 18: 1141.
52.
ZhouFYangXZhaoH, et al. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics2018; 8: 5200-5212.
53.
HanahanDWeinbergRA.Hallmarks of cancer: the next generation. Cell2011; 144: 646-674.
54.
TanWZhongZWangS, et al. The typical metabolic modifiers conferring improvement in cancer resistance. Curr Med Chem2017; 24: 3698-3710.
55.
YiWClarkPMMasonDE, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science2012; 337: 975-980.
56.
NieHJuHFanJ, et al. O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth. Nat Commun2020; 11: 36.
57.
WangYLiuJJinX, et al. O-GlcNAcylation destabilizes the active tetrameric PKM2 to promote the Warburg effect. Proc Natl Acad Sci U S A2017; 114: 13732-13737.
58.
FerrerCMLynchTPSodiVL, et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell2014; 54: 820-831.
59.
WongYKWangJLimTK, et al. O-GlcNAcylation promotes fatty acid synthase activity under nutritional stress as a pro-survival mechanism in cancer cells. Proteomics2022; 22: e2100175.
60.
SodiVLBacigalupaZAFerrerCM, et al. Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation. Oncogene2018; 37: 924-934.
61.
TanWJiangPZhangW, et al. Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation. Mol Cell2021; 81: 1890-1904.e7.
62.
ChenLZhouQZhangP, et al. Direct stimulation of de novo nucleotide synthesis by O-GlcNAcylation. Nat Chem Biol2023; 20: 19-29.
63.
HouDYXiaoWYWangJQ, et al. OGA activated glycopeptide-based nano-activator to activate PKM2 tetramerization for switching catabolic pathways and sensitizing chemotherapy resistance. Biomaterials2022; 284: 121523.
64.
CurtinNJ.DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer2012; 12: 801-817.
65.
ShekharMP.Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets2011; 11: 613-623.
66.
XieKDolesJHemannMT, et al. Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A2010; 107: 20792-20797.
67.
MaXLiuHLiJ, et al. Polη O-GlcNAcylation governs genome integrity during translesion DNA synthesis. Nat Commun2017; 8: 1941.
68.
HousmanGBylerSHeerbothS, et al. Drug resistance in cancer: an overview. Cancers (Basel)2014; 6: 1769-1792.
69.
NoachNSegevYLeviI, et al. Modification of topoisomerase I activity by glucose and by O-GlcNAcylation of the enzyme protein. Glycobiology2007; 17: 1357-1364.
70.
ChenQYuX.OGT restrains the expansion of DNA damage signaling. Nucleic Acids Res2016; 44: 9266-9278.
71.
ZhouYZhangYPengC, et al. And-1 O-GlcNAcylation regulates homologous recombination repair and radioresistance in colorectal cancer. Clin Transl Med2022; 12: e785.
72.
MiuraYSakuraiYEndoT.O-GlcNAc modification affects the ATM-mediated DNA damage response. Biochim Biophys Acta2012; 1820: 1678-1685.
73.
EfimovaEVAppelbeOKRiccoN, et al. O-GlcNAcylation enhances double-strand break repair, promotes cancer cell proliferation, and prevents therapy-induced senescence in irradiated tumors. Mol Cancer Res2019; 17: 1338-1350.
74.
TianYZhuQSunZ, et al. One-step enzymatic labeling reveals a critical role of o-glcnacylation in cell-cycle progression and DNA damage response. Angew Chem Int Ed Engl2021; 60: 26128-26135.
75.
BalanaATMukherjeeANagpalH, et al. O-GlcNAcylation of high mobility group box 1 (HMGB1) alters its DNA binding and DNA damage processing activities. J Am Chem Soc2021; 143: 16030-16040.
76.
ErinNGrahovacJBrozovicA, et al. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat2020; 53: 100715.
77.
SurdzielEClayINigschF, et al. Multidimensional pooled shRNA screens in human THP-1 cells identify candidate modulators of macrophage polarization. PLoS One2017; 12: e0183679.
78.
JhaAKHuangSCSergushichevA, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity2015; 42: 419-430.
79.
ShiQShenQLiuY, et al. Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance. Cancer Cell2022; 40: 1207-1222.e10.
80.
Rodrigues MantuanoNStanczakMAOliveiraIA, et al. Hyperglycemia enhances cancer immune evasion by inducing alternative macrophage polarization through increased O-GlcNAcylation. Cancer Immunol Res2020; 8: 1262-1272.
81.
HinshawDCHannaALama-SherpaT, et al. Hedgehog signaling regulates metabolism and polarization of mammary tumor-associated macrophages. Cancer Res2021; 81: 5425-5437.
82.
MoriwakiKAsahiM.Augmented TME O-GlcNAcylation promotes tumor proliferation through the inhibition of p38 MAPK. Mol Cancer Res2017; 15: 1287-1298.
83.
LiXGongWWangH, et al. O-GlcNAc transferase suppresses inflammation and necroptosis by targeting receptor-interacting serine/threonine-protein kinase 3. Immunity2019; 50: 1115.
84.
ShimizuMTanakaN.IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells. Oncogene2019; 38: 1520-1533.
85.
AkellaNMLe MinhGCirakuL, et al. O-GlcNAc transferase regulates cancer stem-like potential of breast cancer cells. Mol Cancer Res2020; 18: 585-598.
86.
LiuBSalgadoOCSinghS, et al. The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation. Nat Commun2019; 10: 354.
87.
YuanYWangLGeD, et al. Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8(+) T cells. Cancer Lett2021; 500: 98-106.
88.
LiTLiXAttriKS, et al. O-GlcNAc transferase links glucose metabolism to MAVS-mediated antiviral innate immunity. Cell Host Microbe2018; 24: 791-803.e6.
89.
FeinbergDRamakrishnanPWongDP, et al. Inhibition of O-GlcNAcylation decreases the cytotoxic function of natural killer cells. Front Immunol2022; 13: 841299.
90.
LiuRMaXChenL, et al. MicroRNA-15b suppresses Th17 differentiation and is associated with pathogenesis of multiple sclerosis by targeting O-GlcNAc transferase. J Immunol2017; 198: 2626-2639.
91.
WuJLChiangMFHsuPH, et al. O-GlcNAcylation is required for B cell homeostasis and antibody responses. Nat Commun2017; 8: 1854.
92.
SommersCLHeckfordSESkerkerJM, et al. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines. Cancer Res1992; 52: 5190-5197.
93.
ParkSYKimHSKimNH, et al. Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. Embo J2010; 29: 3787-3796.
94.
NietoMAHuangRYJacksonRA, et al. EMT: 2016. Cell2016; 166: 21-45.
95.
BiwiJClarisseCBiotC, et al. OGT controls the expression and the glycosylation of E-cadherin, and affects glycosphingolipid structures in human colon cell lines. Proteomics2019; 19: e1800452.
96.
TarbetHJDolatLSmithTJ, et al. Site-specific glycosylation regulates the form and function of the intermediate filament cytoskeleton. Elife2018; 7: e31807.
97.
KimYJKangMJKimE, et al. O-GlcNAc stabilizes SMAD4 by inhibiting GSK-3β-mediated proteasomal degradation. Sci Rep2020; 10: 19908.
98.
Harosh-DavidovichSBKhalailaI. O-GlcNAcylation affects β-catenin and E-cadherin expression, cell motility and tumorigenicity of colorectal cancer. Exp Cell Res2018; 364: 42-49.
99.
ChengSMaoQDongY, et al. GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer. PLoS One2017; 12: e0182696.
100.
ZhangNZhuTYuK, et al. Elevation of O-GlcNAc and GFAT expression by nicotine exposure promotes epithelial-mesenchymal transition and invasion in breast cancer cells. Cell Death Dis2019; 10: 343.
101.
CiesielskiPJóźwiakPFormaE, et al. TET3- and OGT-dependent expression of genes involved in epithelial-mesenchymal transition in endometrial cancer. Int J Mol Sci2021; 22: 13239.
102.
MaddenECGormanAMLogueSE, et al. Tumour cell secretome in chemoresistance and tumour recurrence. Trends Cancer2020; 6: 489-505.
103.
KumarSStokesJ3rdSinghUP, et al. Targeting Hsp70: A possible therapy for cancer. Cancer Lett2016; 374: 156-166.
104.
ChaiyawatPWeeraphanCNetsirisawanP, et al. Elevated O-GlcNAcylation of extracellular vesicle proteins derived from metastatic colorectal cancer cells. Cancer Genomics Proteomics2016; 13: 387-398.
105.
Oliveira-NunesMCJuliãoGMenezesA, et al. O-GlcNAcylation protein disruption by Thiamet G promotes changes on the GBM U87-MG cells secretome molecular signature. Clin Proteomics2021; 18: 14.
106.
DjeuJYWeiS.Clusterin and chemoresistance. Adv Cancer Res2009; 105: 77-92.
107.
KimMJChoiMYLeeDH, et al. O-linked N-acetylglucosamine transferase enhances secretory clusterin expression via liver X receptors and sterol response element binding protein regulation in cervical cancer. Oncotarget2018; 9: 4625-4636.
108.
LiuJRenLLiS, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B2021; 11: 2783-2797.
109.
XavierCPRBelisarioDCRebeloR, et al. The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells. Drug Resist Updat2022; 62: 100833.
110.
ChenRLaiLASullivanYChenR, et al. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Sci Rep2017; 7: 7950.
111.
AmirianRAzadi BadrbaniMIzadiZ, et al. Targeted protein modification as a paradigm shift in drug discovery. Eur J Med Chem2023; 260: 115765.
112.
IngramJRSchmidtFIPloeghHL.Exploiting nanobodies' singular traits. Annu Rev Immunol2018; 36: 695-715.
113.
RamirezDHAonbangkhenCWuHY, et al. Engineering a proximity-directed O-GlcNAc transferase for selective protein O-GlcNAcylation in cells. ACS Chem Biol2020; 15: 1059-1066.
114.
GeYRamirezDHYangB, et al. Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase. Nat Chem Biol2021; 17: 593-600.
115.
UpadhyayAKandiRRaoCP.Wheat germ agglutinin modified magnetic iron oxide nanocomplex as a cell membrane specific receptor target material for killing breast cancer cells. J Mater Chem B2018; 6: 5729-5737.
116.
AudfrayABeldjoudiMBreimanA, et al. A recombinant fungal lectin for labeling truncated glycans on human cancer cells. PLoS One2015; 10: e0128190.
117.
LinBChaiSZhangQ, et al. Sialic acid-modified O-GlcNAc transferase inhibitor liposome presents antitumor effect in hepatocellular carcinoma. Mol Pharm2024; 21: 102-112.
118.
ItkonenHMPouloseNSteeleRE, et al. Inhibition of O-GlcNAc transferase renders prostate cancer cells dependent on CDK9. Mol Cancer Res2020; 18: 1512-1521.
119.
WangZQinJZhaoJ, et al. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Theranostics2020; 10: 7178-7192.
120.
RicciardielloFGangYPaloriniR, et al. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. Oncogene2020; 39: 4103-4117.
121.
RicciardielloFBergamaschiLDe VittoH, et al. Suppression of the HBP function increases pancreatic cancer cell sensitivity to a pan-RAS inhibitor. Cells2021; 10: 431.
122.
SharmaNSGuptaVKGarridoVT, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest2020; 130: 451-465.
123.
HuangYJChenYTHuangCM, et al. HIF-1α expression increases preoperative concurrent chemoradiotherapy resistance in hyperglycemic rectal cancer. Cancers (Basel)2022; 14: 4053.
124.
HuaQLuYWangD, et al. KIAA1199 promotes oxaliplatin resistance and epithelial mesenchymal transition of colorectal cancer via protein O-GlcNAcylation. Transl Oncol2023; 28: 101617.
125.
PepeFPagottoSSolimanS, et al. Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells. Oncogenesis2017; 6: e328.
126.
LiuYCaoYPanX, et al. O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance. Cell Death Dis2018; 9: 485.
127.
LeeHWKangMJKwonYJ, et al. Targeted inhibition of O-Linked β-N-Acetylglucosamine transferase as a promising therapeutic strategy to restore chemosensitivity and attenuate aggressive tumor traits in chemoresistant urothelial carcinoma of the bladder. Biomedicines2022; 10: 1162.
128.
MakwanaVDukieASRudrawarS.Investigating the impact of OGT inhibition on doxorubicin- and docetaxel-induced cytotoxicity in PC-3 and WPMY-1 cells. Int J Toxicol2020; 39: 586-593.
129.
SekineHOkazakiKKatoK, et al. O-GlcNAcylation signal mediates proteasome inhibitor resistance in cancer cells by stabilizing NRF1. Mol Cell Biol2018; 38: e00252-18.
130.
HashimotoEOkunoSHirayamaS, et al. Enhanced O-GlcNAcylation mediates cytoprotection under proteasome impairment by promoting proteasome turnover in cancer cells. iScience2020; 23: 101299.
131.
DengXYiXHuangD, et al. ROCK2 mediates osteosarcoma progression and TRAIL resistance by modulating O-GlcNAc transferase degradation. Am J Cancer Res2020; 10: 781-798.
